Ignite Creation Date:
2025-12-24 @ 12:04 PM
Ignite Modification Date:
2025-12-27 @ 9:28 PM
Study NCT ID:
NCT02684461
Status:
COMPLETED
Last Update Posted:
2022-06-03
First Post:
2016-02-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LCCC 1516
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |